A Randomized, Open-Label, Single-Dose, 2 Period Crossover Pharmacokinetic and Bioequivalence Study, With a Lead-In Dose Period, Evaluating Oral Abacavir Acetate (Prurisol) and Oral Abacavir Sulfate (Ziagen) in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2015
At a glance
- Drugs Abacavir (Primary)
- Indications Psoriasis
- Focus First in man; Pharmacokinetics
- Sponsors Cellceutix
- 24 Sep 2014 Status changed from active, no longer recruiting to completed.
- 07 Aug 2014 Results of primary endpoint published in Cellceutix media release.
- 07 Aug 2014 Primary endpoint (bioequivalence of Prurisol and Ziagen, as determined by AUC) has been met, according to Cellceutix media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History